Loading clinical trials...

Promoting Positive Emotional Functioning in Police and Military Populations | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

Promoting Positive Emotional Functioning in Police and Military Populations

NCT06035562•University of Manitoba

Summary

This study will examine whether actively serving and veteran members of the Canadian Armed Forces (CAF) and Royal Canadian Mounted Police (RCMP) who complete a treatment targeting anhedonia symptoms and amplifying positive emotional processing: 1) experience significant symptom reductions in anxiety, trauma, and depressive symptoms; 2) report increased experience of positive emotions; 3) report improvements to broad functioning and quality of life; and 4) find the treatment to be highly tolerable.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Be an actively serving or veteran member of the CAF and RCMP;
•Have been referred to receive the treatment protocol at the OSIC at Deer Lodge Centre by a doctor or psychologist;
•Have previously participated in at least one evidence-based psychological treatment for depressive, anxiety, or trauma-and-stressor-related condition at OSIC but remain clinically symptomatic;
•Be able to speak, read, and write in English;
•Have no current psychosis, untreated bipolar disorder, or current suicidal ideation with plan and intent;
•Be on a stable medication regime and agree to not make changes for the duration of the treatment.

Locations (1)

Deer Lodge Centre

Winnipeg, Manitoba, Canada

Key Dates

Start Date

September 5, 2023

Primary Completion Date

May 12, 2025

Completion Date

August 1, 2025

Last Updated

June 4, 2025

Enrollment

ESTIMATED participants

Conditions

Anhedonia

Interventions

PVSET

BEHAVIORAL

Developing Brain Imaging Analysis Expertise for Personalizing Transcranial Electric Stimulation in Anhedonia Treatment of Patients With Bipolar Depression

NCT05240352

Anhedonia

View study

RECRUITING

Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression

NCT07146503

Depression and Quality of LifeTreatment Resistant Depression (TRD)+6 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 4, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Promoting Positive Emotional Functioning in Police and Military Populations

Inclusion Criteria

Developing Brain Imaging Analysis Expertise for Personalizing Transcranial Electric Stimulation in Anhedonia Treatment of Patients With Bipolar Depression

Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression

Inflammation and Depression in People With HIV

Reward Processing and Depressive Subtypes: Identifying Neural Biotypes

Psilocybin for Treatment-Resistant Depression

tVNS and Approach-Avoidance Behavior in Anhedonia and Anxiety